Agilent Technologies (NYSE:A) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Agilent Technologies (NYSE:A) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $157.00 target price on the medical research company’s stock.

A has been the topic of a number of other research reports. Robert W. Baird decreased their target price on shares of Agilent Technologies from $147.00 to $136.00 and set an outperform rating on the stock in a report on Thursday, May 30th. Stifel Nicolaus reaffirmed a buy rating and set a $151.00 target price on shares of Agilent Technologies in a report on Monday. Citigroup upped their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a buy rating in a report on Thursday, August 22nd. JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an overweight rating on the stock in a report on Thursday, May 30th. Finally, Jefferies Financial Group reissued a hold rating and issued a $135.00 price target (down previously from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $141.60.

Agilent Technologies Stock Up 1.0 %

A opened at $142.53 on Tuesday. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34. The stock has a market cap of $41.58 billion, a price-to-earnings ratio of 33.70, a PEG ratio of 4.86 and a beta of 1.05. Agilent Technologies has a twelve month low of $96.80 and a twelve month high of $155.35. The company’s 50-day moving average price is $134.59 and its two-hundred day moving average price is $138.72.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the previous year, the company earned $1.43 earnings per share. The company’s quarterly revenue was down 5.6% on a year-over-year basis. As a group, equities analysts expect that Agilent Technologies will post 5.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the sale, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the sale, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at approximately $3,497,110. The disclosure for this sale can be found here. Insiders have sold a total of 20,874 shares of company stock valued at $2,811,770 in the last quarter. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Crewe Advisors LLC lifted its position in Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 101 shares during the period. Livelsberger Financial Advisory purchased a new position in Agilent Technologies in the fourth quarter worth about $26,000. VisionPoint Advisory Group LLC purchased a new position in Agilent Technologies in the fourth quarter worth about $29,000. Ridgewood Investments LLC purchased a new position in Agilent Technologies in the second quarter worth about $29,000. Finally, Rise Advisors LLC raised its holdings in Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after buying an additional 190 shares during the last quarter. 87.42% of the stock is owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.